Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
Miauton A., Audran R., Besson J., Maby-El Hajjami H., Karlen M., Warpelin-Decrausaz L., Sene L., Schaufelberger S., Faivre V., Faouzi M. et al., 2024/01. EBioMedicine, 99 p. 104922. Peer-reviewed.
ici le détail